jinjian lu

Jin Jian Lu 陸金健

Associate Professor
Programme Coordinator of Chinese Medicinal Science

 

Dr. Lu has published more than 160 scientific papers in the SCI journals, such as Pharmacology & Therapeutics, Journal of Hematology & Oncology, Cancer Letters, Drug Discovery Today, etc. (Total Citations 5000+, h index=41, google scholar)

*Corresponding or co-corresponding author, #Co-first author. Please click here for the full publications.

https://www.researchgate.net/profile/Jin-Jian_Lu

https://scholar.google.com/citations?user=G7DwcegAAAAJ&hl=en

  1. Huang MY, Jiang XM, Wang BL, Sun Y, Lu JJ*. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacology & Therapeutics. 2020, In Press.
  2. Yu WB, Ye ZH, Chen X, Shi JJ*, Lu JJ*. The development of small-molecule inhibitors targeting CD47. Drug Discovery Today, 2020, In Press.
  3. Yuan LW, Jiang XM, Xu YL, Huang MY, Chen YC, Yu WB, Su MX, Ye ZH, Chen X, Wang Y, Lu JJ*. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells. Phytomedicine. 2020, In Press.
  4. Li T, Xu XH, Guo X, Yuan T, Tang ZH, Jiang XM, Xu YL, Zhang LL, Chen X, Zhu H, Shi JJ, Lu JJ*. Activation of Notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus. Biochemical Pharmacology. 2020, 175: 113921.
  5. Jiang XM, Xu YL, Yuan LW, Zhang LL, Huang MY, Ye ZH, Su MX, Chen X, Zhu H, Ye R, Lu JJ*. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance. Acta Pharmacologica Sinica. 2020, In Press.
  6. Zhang LL, Guo J, Jiang XM, Chen X, Wang Y, Li A, Lin LG*, Li H*, Lu JJ*. Identification of nagilactone E as a protein synthesis inhibitor with anticancer activity. Acta Pharmacologica Sinica. 2020, 41: 698-705.
  7. Zhang LL, Huang MY, Yang Y, Huang MQ, Shi JJ, Zou L*, Lu JJ*. Bioactive platycodins from Platycodonis Radix: phytochemistry, pharmacological activities, toxicology and pharmacokinetics. Food Chemistry. 2020, 327: 127029.
  8. Huang MY, Jiang XM*, Xu YL, Yuan LW, Chen YC, Cui G, Huang RY, Liu B, Wang Y, Chen X, Lu JJ*. Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells. Food and Chemical Toxicology. 2019, 131: 110537.
  9. Zhang LL, Jiang XM, Huang MY, Feng ZL, Chen X, Wang Y, Li H, Li A, Lin LG*, Lu JJ*. Nagilactone E suppresses TGF-β1-induced epithelial–mesenchymal transition, migration and invasion in non-small cell lung cancer cells. Phytomedicine. 2019, 52: 32-9.
  10. Cao WX, Li T, Tang ZH, Zhang LL, Wang ZY, Guo X, Su MX, Chen X, Lu JJ*. MLKL mediates apoptosis via a mutual regulation with PERK/eIF2α pathway in response to reactive oxygen species generation. Apoptosis. 2018, 23(9-10): 521-31.
  11. Li T, Jiang HL, Tong YG, Lu JJ*. Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery. Journal of Hematology & Oncology. 2018, 11: 59.
  12. Tang ZH, Cao WX, Guo X, Dai XY, Lu JH, Chen X, Zhu H, Lu JJ*. Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer. Cancer Letters. 2018, 412: 1-9.
  13. Tang ZH, Lu JJ*. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Letters. 2018, 420: 242-6.
  14. Huang MY, Zhang LL, Ding J, Lu JJ*. Anticancer drug discovery from Chinese medicinal herbs. Chinese Medicine. 2018, 13: 35. (Invited Review)
  15. Jiang XM, Xu YL, Huang MY, Zhang LL, Su MX, Chen XP, Lu JJ*. Osimertinib (AZD9291) decreases PD-L1 in EGFR-mutated non-small cell lung cancer cells. Acta Pharmacologica Sinica. 2017, 38(11): 1512-20.
  16. Li T, Chen X, Dai XY, Wei B, Weng QJ, Chen X, Ouyang DF, Yan R, Huang ZJ, Jiang HL, Zhu H, Lu JJ*. Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor. Toxicology and Applied Pharmacology. 2017, 330: 65-73.
  17. Tang ZH, Cao WX, Wang ZY, Lu JH, Liu B, Chen XP, Lu JJ*. Induction of reactive oxygen species-stimulated distinctive autophagy by chelerythrine in non-small cell lung cancer cells. Redox Biology. 2017, 12: 367-76.
  18. Lu JJ, Pan W, Hu YJ*, Wang YT*. Multi-target drugs: The trend of drug research and development. PLoS ONE. 2012, 7(6): e40262. (Highly Cited Paper)
  19. Tan W, Lu JJ#, Huang MQ, Li YB, Chen MW, Wu GS, Gong J, Zhong ZF, Xu ZT, Dang YY, Guo JJ, Chen XP*, Wang YT*. Anti-cancer natural products isolated from Chinese medicinal herbs. Chinese Medicine. 2011, 6: 27. (Highly Cited Paper)
  20. Lu JJ, Meng LH*, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J*. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochemical Pharmacology. 2010, 80(1):22-30.

Book Chapters

  1. Pharmacology in Chinese medicines (3rd Edition). Shanghai Scientific & Technical Publishers. ISBN: 978-7-5478-4239-3/R·1738. January 2019. (In Chinese only)
  2. Advances of Chinese medicines for cancer therapy. People’s Medical Publishing House Co. LTD. ISBN: 978-7-117-16227-2/R·16228. October, 2012. (In Chinese only)
  • CNPHARS Annual Young Pharmacologists Award (2016)
  • Member of 2nd Prize of Natural Science: Macao Science and Technology Awards (2014)
  • Member of 2nd Prize of Natural Science: Macao Science and Technology Awards (2012)

Editorial / Youth Editorial Board Member

  • Translational Oncology (SCI)
  • Current Molecular Pharmacology (SCI)
  • Anti-Cancer Agents in Medicinal Chemistry (SCI)
  • Chinese Medicines (SCI)
  • Chinese Journal of Natural Medicines (SCI)
  • Molecular Medicine Reports (SCI)
  • World Journal of Traditional Chinese Medicine
  • Chinese Journal of Cancer Prevention and Treatment
  • Journal of Jiangsu University (Medicine Edition)

Peer Reviewer (Project)

  • National Natural Science Foundation of China
  • Zhejiang Provincial Natural Science Foundation
  • Academic Degree & Graduate Education Evaluation of MOE
  • China Adolescents Science & Technology Innovation Contest

Peer Reviewer (Journal)

As a reviewer for 100+ scientific journals. Dr. Lu won the honors of outstanding reviewer in multiple journals, such as Acta Pharmacologica Sinica, Chinese Journal of Natural Medicines, European Journal of Pharmacology, Journal of Ethnopharmacology, Phytomedicine, etc. Representative journals include,

  • Acta Pharmaceutica Sinica B
  • Acta Pharmacologica Sinica
  • Autophagy
  • Biochemical Pharmacology
  • Biomaterial
  • Drug Discovery Today
  • European Journal of Pharmacology
  • Free Radical Biology and Medicine
  • Journal of Agricultural and Food Chemistry
  • Journal of Ethnopharmacology
  • Journal of Experimental & Clinical Cancer Research
  • Pharmacological Research
  • Phytomedicine
  • Phytotherapy Research
  • The FASEB Journal